Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma

1 Dec 2017

Abstract excerpt

BACKGROUND: PCDH10, one of the non-clustered protocadherins, is identified as a tumor suppressor gene in many tumors. Recently, promoter methylation of PCDH10 was found in diffuse large B-cell lymphoma (DLBCL) but not in normal lymph nodes, suggesting that its epigenetic aberrance is essential to the lymphomagenesis. However, there are few studies on the clinicopathological relevance and prognostic significance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Lymphoma Diagnosis and Treatment
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29202805
DOI: 10.1186/s12885-017-3810-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphomaPMID 29202805Read ↗

Clinical Significance of the Methylated Cytosine-Phosphate-Guanine Sites of Protocadherin-10 Promoter for Evaluating the Prognosis of Gastric CancerSemantic proximity Read ↗

High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.Semantic proximity Read ↗

Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancerSemantic proximity Read ↗

Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphomaSemantic proximity Read ↗

Down-regulated of PCDH10 predicts poor prognosis in hepatocellular carcinoma patientsSemantic proximity Read ↗

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphomaSemantic proximity Read ↗

Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancerSemantic proximity Read ↗

E3 ubiquitin ligase RNF180 prevents excessive PCDH10 methylation to suppress the proliferation and metastasis of gastric cancer cells by promoting ubiquitination of DNMT1Semantic proximity Read ↗

DNA methylation patterns in EBV-positive and EBV-negative Hodgkin lymphomasSemantic proximity Read ↗

Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer.Semantic proximity Read ↗

Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.